Halfway through 5-year study, ExoDx Prostate Test offers more accurate stratification of high- and low-risk patients compared to standard of care MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Bio-Techne ...
MINNEAPOLIS, April 15, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced today that Exosome Diagnostics, a Bio-Techne brand, is launching an ExoDx™ Prostate Test At-Home Collection ...
MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx ...
On August 5, 2025, mdxhealth signed a definitive agreement to acquire Exosome Diagnostics, Inc. from Bio-Techne, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback